Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LNTH 
Lantheus Holdings Inc (LNTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: LNTH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $86.64
1 Year Target Price $86.64
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.12% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.53B USD | Price to earnings Ratio 13.82 | 1Y Target Price 86.64 |
Price to earnings Ratio 13.82 | 1Y Target Price 86.64 | ||
Volume (30-day avg) 13 | Beta 0.15 | 52 Weeks Range 47.25 - 118.21 | Updated Date 09/17/2025 |
52 Weeks Range 47.25 - 118.21 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 17.82% | Operating Margin (TTM) 23.27% |
Management Effectiveness
Return on Assets (TTM) 13.34% | Return on Equity (TTM) 24.71% |
Valuation
Trailing PE 13.82 | Forward PE 8.56 | Enterprise Value 3454257865 | Price to Sales(TTM) 2.32 |
Enterprise Value 3454257865 | Price to Sales(TTM) 2.32 | ||
Enterprise Value to Revenue 2.27 | Enterprise Value to EBITDA 7.55 | Shares Outstanding 67994200 | Shares Floating 63181523 |
Shares Outstanding 67994200 | Shares Floating 63181523 | ||
Percent Insiders 2.24 | Percent Institutions 117.21 |
Upturn AI SWOT
Lantheus Holdings Inc
Company Overview
History and Background
Lantheus Holdings, Inc. was founded in 1956. It initially focused on contrast agents and diagnostic imaging. Over time, it expanded its portfolio and shifted towards precision diagnostics and therapies.
Core Business Areas
- Precision Diagnostics: Develops, manufactures, and distributes diagnostic imaging agents that help physicians visualize and assess diseases in the body. Includes products for cardiac, cancer and other diseases.
- Therapeutic Applications: Focuses on developing and commercializing therapeutics, particularly in the field of prostate cancer.
Leadership and Structure
The CEO of Lantheus Holdings is Mary Anne Heino. The company has a typical corporate structure with departments such as R&D, Sales & Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- Pylarify: A PSMA-targeted PET imaging agent used for prostate cancer staging. Pylarify is a leading product for Lantheus, with strong growth and high profit margins. It has a significant market share. Competitors include Blue Earth Diagnostics and Progenics Pharmaceuticals (now part of Lantheus).
- DEFINITY: An ultrasound contrast agent used to enhance cardiac imaging. It is a well-established product with a solid market share, competing with GE Healthcare and Bracco Diagnostics.
Market Dynamics
Industry Overview
The diagnostic imaging market is growing, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. The market is competitive, with many players offering various imaging modalities and contrast agents.
Positioning
Lantheus is positioned as a leader in precision diagnostics and therapeutics, particularly in prostate cancer imaging. Its competitive advantage lies in its innovative products, strong distribution network, and focus on specialized areas.
Total Addressable Market (TAM)
The overall nuclear medicine and precision diagnostics market is estimated to be worth billions of dollars annually. Lantheus is focused on capturing a significant share of the market, particularly in the prostate cancer imaging segment.
Upturn SWOT Analysis
Strengths
- Strong product portfolio with leading positions in key markets
- Innovative products and technologies
- Experienced management team
- Established distribution network
Weaknesses
- Reliance on a few key products
- Exposure to regulatory risks
- Competition from larger players
- Potential for product obsolescence due to technological advancements
Opportunities
- Expanding into new therapeutic areas
- Acquiring complementary technologies and products
- Partnering with other companies to expand market reach
- Developing new diagnostic imaging agents
Threats
- Increased competition
- Pricing pressures
- Changes in reimbursement policies
- Product liability claims
Competitors and Market Share
Key Competitors
- GE (GE)
- BRACCO DIAGNOSTICS
- IBA Molecular
Competitive Landscape
Lantheus competes with larger, more diversified companies. Lantheus's competitive advantage lies in its specialization, innovative products, and strong customer relationships. It needs to continue to innovate and expand its portfolio to maintain its market position.
Major Acquisitions
Progenics Pharmaceuticals
- Year: 2020
- Acquisition Price (USD millions): 250
- Strategic Rationale: To expand its pipeline of radiopharmaceutical oncology products, particularly targeting prostate cancer.
Growth Trajectory and Initiatives
Historical Growth: Lantheus has experienced solid growth in recent years, driven by strong sales of its key products, particularly Pylarify.
Future Projections: Future growth is projected to be driven by continued adoption of Pylarify, expansion into new therapeutic areas, and strategic acquisitions.
Recent Initiatives: Recent initiatives include the acquisition of Progenics Pharmaceuticals, the launch of new products, and expansion of its manufacturing capacity.
Summary
Lantheus is a strong company in the precision diagnostics market. The company's prostate cancer imaging portfolio, particularly Pylarify, is driving growth. Lantheus needs to be careful to maintain its market share against larger competitors, while also expanding its pipeline to decrease reliance on a single key product.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lantheus Holdings Investor Relations
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share is an estimate based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantheus Holdings Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2015-06-25 | CEO & Director Mr. Brian A. Markison | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 808 | Website https://www.lantheus.com |
Full time employees 808 | Website https://www.lantheus.com | ||
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.